Regen BioPharma, Inc.
RGBP
$0.055
$0.0011.85%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 236.70K | 236.70K | 236.70K | 236.70K | 236.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 236.70K | 236.70K | 236.70K | 236.70K | 236.70K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 236.70K | 236.70K | 236.70K | 236.70K | 236.70K |
| SG&A Expenses | 501.00K | 471.90K | 436.60K | 418.10K | 711.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 654.60K | 627.40K | 604.60K | 582.40K | 923.50K |
| Operating Income | -418.30K | -391.00K | -368.20K | -345.90K | -687.00K |
| Income Before Tax | -867.30K | -927.40K | -896.50K | -829.00K | 1.16M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.87 | -0.93 | -0.90 | -0.83 | 1.16 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -867.30K | -927.40K | -896.50K | -829.00K | 1.16M |
| EBIT | -418.30K | -391.00K | -368.20K | -345.90K | -687.00K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.11 | -0.11 | -0.11 | -0.11 | 0.15 |
| Normalized Basic EPS | -0.05 | -0.06 | -0.06 | -0.06 | 0.11 |
| EPS Diluted | -0.11 | -0.11 | -0.11 | -0.11 | 0.15 |
| Normalized Diluted EPS | -0.05 | -0.06 | -0.06 | -0.06 | 0.11 |
| Average Basic Shares Outstanding | 32.54M | 31.58M | 29.91M | 25.34M | 24.87M |
| Average Diluted Shares Outstanding | 32.54M | 31.58M | 29.91M | 25.34M | 24.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |